uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis
Univ Eastern Finland, Dept Mol Med, AI Virtanen Inst, Kuopio, Finland..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centre for Research and Development, Gävleborg.
Univ Clin Schleswig Holstein, Inst Pathol, Campus Kiel, Kiel, Germany..
Max Delbruck Ctr Mol Med, Berlin, Germany..
Show others and affiliations
2016 (English)In: Arteriosclerosis, Thrombosis and Vascular Biology, ISSN 1079-5642, E-ISSN 1524-4636, Vol. 36, no 8, 1534-1548 p.Article in journal (Refereed) Published
Abstract [en]

Objective Drug-eluting coronary stents reduce restenosis rate and late lumen loss compared with bare-metal stents; however, drug-eluting coronary stents may delay vascular healing and increase late stent thrombosis. The peroxisome proliferator-activated receptor-delta (PPAR) exhibits actions that could favorably influence outcomes after drug-eluting coronary stents placement. Approach and Results Here, we report that PPAR ligand-coated stents strongly reduce the development of neointima and luminal narrowing in a rabbit model of experimental atherosclerosis. Inhibition of inflammatory gene expression and vascular smooth muscle cell (VSMC) proliferation and migration, prevention of thrombocyte activation and aggregation, and proproliferative effects on endothelial cells were identified as key mechanisms for the prevention of restenosis. Using normal and PPAR-depleted VSMCs, we show that the observed effects of PPAR ligand GW0742 on VSMCs and thrombocytes are PPAR receptor dependent. PPAR ligand treatment induces expression of pyruvate dehydrogenase kinase isozyme 4 and downregulates the glucose transporter 1 in VSMCs, thus impairing the ability of VSMCs to provide the increased energy demands required for growth factor-stimulated proliferation and migration. Conclusions In contrast to commonly used drugs for stent coating, PPAR ligands not only inhibit inflammatory response and proliferation of VSMCs but also prevent thrombocyte activation and support vessel re-endothelialization. Thus, pharmacological PPAR activation could be a promising novel strategy to improve drug-eluting coronary stents outcomes.

Place, publisher, year, edition, pages
2016. Vol. 36, no 8, 1534-1548 p.
Keyword [en]
blood platelets, coronary in-stent restenosis, endothelial cells, peroxisome proliferator-activated receptors, vascular smooth muscle cells
National Category
Hematology Cardiac and Cardiovascular Systems
URN: urn:nbn:se:uu:diva-304228DOI: 10.1161/ATVBAHA.115.306962ISI: 000381474000010PubMedID: 27283742OAI: oai:DiVA.org:uu-304228DiVA: diva2:1048376

Jarkko Hytönen and Olli Leppänen contributed equally to this work.

Available from: 2016-11-21 Created: 2016-10-03 Last updated: 2016-11-24Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Centre for Research and Development, Gävleborg
In the same journal
Arteriosclerosis, Thrombosis and Vascular Biology
HematologyCardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 58 hits
ReferencesLink to record
Permanent link

Direct link